Virus-Like Particles (VLPs) Production in Yeast Cell System

Creative Biolabs has been long-term committed to developing virus-like particle (VLP) technology in yeast cells system. We are honored to use our advanced platforms and extensive experience to serve our valued customer with the best service and the most qualified products.

Virus-like particles (VLPs) are multiprotein structures which resemble the conformation of native viruses while lacking a viral genome, potentiating their application as cheaper and safer vaccines and immunogens. In addition, VLPs are also frequently applied in membrane protein expression, delivery systems, bioimaging and cell targeting, and many other fields.

Representative pictures of virus-like particles (VLPs) under electron microscopy Figure 1. Representative pictures of virus-like particles (VLPs) under electron microscopy. (BMC biotechnology, 2014)

Yeast system manifests as one commonly used cell-based machinery for production of a variety of VLPs from bacterial, yeast, plant and mammalian origin. Hansenula and Pichia strains, two most representative yeast strains, are more biologically complicated than E. coli since yeast vectors need to be propagated in bacteria first and then introduced into yeast cells. However, compared with E. coli, yeast system exhibits multiple critical advantages, such as:

Creative Biolabs has already proven that several mammalian VLPs can be successfully obtained using yeast cells. We now provide multiple yeast strains as powerful expression machinery for VLPs production, including Pichia pastoris, Hansenula polymorpha and saccharomyces cerevisiae, etc.

Creative Biolabs now offers unparalleled virus-like particle (VLPs) service based on yeast cells system. With years of nonstop exploration, our scientists have also established several other expression systems including:

We are able to provide a broad range of VLPs related services from production, optimization, characterization to functionalization strategies. As alternatives, we also provide in-house VLPs products derived from various virus families (e.g. HBV VLP, HIV VLP, HPV VLP, CA16 VLP, EV71 VLP, poliovirus VLP, polyomaviruses VLP, AAV VLP, bacteriophage Qβ VLP, Zika VLP, etc.). Please feel free to inquire us for further discussions.


  1. Shirbaghaee, Z., & Bolhassani, A. (2016). Different applications of virus‐like particles in biology and medicine: Vaccination and delivery systems. Biopolymers, 105(3), 113-132.
  2. Nainys J, Lasickiene R, Petraityte-Burneikiene R, et al. (2014). Generation in yeast of recombinant virus-like particles of porcine circovirus type 2 capsid protein and their use for a serologic assay and development of monoclonal antibodies. BMC biotechnology, 14(1), 100.
  3. Lünsdorf H, Gurramkonda C, Adnan A, et al. (2011). Virus-like particle production with yeast: ultrastructural and immunocytochemical insights into Pichia pastoris producing high levels of the Hepatitis B surface antigen. Microbial cell factories, 10(1), 48.
  4. Freivalds J, Dislers A, Ose V, et al. (2011). Highly efficient production of phosphorylated hepatitis B core particles in yeast Pichia pastoris. Protein expression and purification, 75(2), 218-224.
  5. Rodríguez-Limas W A, Tyo K E J, Nielsen J, et al. (2011). Molecular and process design for rotavirus-like particle production in Saccharomyces cerevisiae. Microbial cell factories, 10(1), 33.

All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic or any in vivo human use.

Online Inquiry

Verification code
Click image to refresh the verification code.


USA: 45-1 Ramsey Road, Shirley, NY 11967, USA
Europe: UK - Germany
Call us at:
USA: 1-631-381-2994
Fax: 1-631-207-8356
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us